End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
52,700 KRW | +1.35% |
|
+0.19% | -26.81% |
Jun. 28 | SK Bioscience to Take Over Germany's IDT Biologika | MT |
Jun. 27 | South Korean shares fall but chipmakers' rebound limits early losses | RE |
Business Summary
Sales per Business
KRW in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Vaccine/Biopharmaceuticals
100.0
%
| 456,726 | 100.0 % | 369,506 | 100.0 % | -19.10% |
Sales per region
KRW in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
America
50.3
%
| 217,834 | 47.7 % | 185,961 | 50.3 % | -14.63% |
South Korea
42.8
%
| 224,157 | 49.1 % | 158,217 | 42.8 % | -29.42% |
Europe
5.7
%
| 13,778 | 3.0 % | 21,202 | 5.7 % | +53.88% |
Asia
1.1
%
| 651 | 0.1 % | 3,893 | 1.1 % | +497.76% |
Middle East
0.1
%
| 305 | 0.1 % | 232 | 0.1 % | -24.07% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Jae-Yong An
CEO | Chief Executive Officer | 56 | - |
Yong-Sung Choi
DFI | Director of Finance/CFO | 51 | - |
Sally Choe
CTO | Chief Tech/Sci/R&D Officer | - | - |
Jong-Gu Park
CTO | Chief Tech/Sci/R&D Officer | 59 | - |
Hun Kim
CTO | Chief Tech/Sci/R&D Officer | 57 | 17-12-31 |
Young-Joo Park
IRC | Investor Relations Contact | 54 | - |
Harry Kleanthous
PRN | Corporate Officer/Principal | - | 22-10-20 |
Ji-Hyun Yoo
LAW | General Counsel | 46 | - |
Su-Ahn Yoo
SAM | Sales & Marketing | 51 | - |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Jeffrey Choi
BRD | Director/Board Member | 60 | - |
Chang-Jin Moon
BRD | Director/Board Member | 71 | - |
Jae-Yong An
CEO | Chief Executive Officer | 56 | - |
Mi-Jin Cho
BRD | Director/Board Member | 62 | - |
Gwang-Hyun Jeon
BRD | Director/Board Member | 59 | - |
Hun Kim
CTO | Chief Tech/Sci/R&D Officer | 57 | 17-12-31 |
Ik-Hwan Kwon
BRD | Director/Board Member | 57 | - |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 76,827,750 | 24,186,505 ( 31.48 %) | 0 | 31.48 % |
Holdings
Name | Equities | % | Valuation |
---|---|---|---|
NOVAVAX, INC. 4.63% | 6,500,000 | 4.63% | 97,695,000 $ |
Company contact information
SK bioscience Co., Ltd.
310 Pangyo-ro Bundang-gu
13494, Seongnam-si
+82 2 2008 2200
http://www.skbioscience.co.kr![address SK bioscience Co.,Ltd.(A302440)](https://cdn.zonebourse.com/static/address/120803076.png)
Sector
Sales per region
![Consensus](/images/consensus_flch.gif)
EPS Revisions
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-26.81% | 2.93B | |
+4.57% | 97.7B | |
+5.66% | 41.43B | |
-12.80% | 32.85B | |
+80.99% | 29.33B | |
-15.53% | 15.47B | |
-8.70% | 12.89B | |
-12.22% | 11.51B | |
+183.25% | 10.74B | |
-55.41% | 8.97B |
- Stock Market
- Equities
- A302440 Stock
- Company SK bioscience Co.,Ltd.